Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease

BACKGROUND: Sodium–glucose cotransporter-2 (SGLT2) inhibitors are cardioprotective agents in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease (CVD). Since little is known about their uptake in atherosclerotic CVD, we examined SGLT2 inhibitor prescribing trends and id...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozaki, Aya F., Ko, Dennis T., Chong, Alice, Fang, Jiming, Atzema, Clare L., Austin, Peter C., Stukel, Therese A., Tu, Karen, Udell, Jacob A., Naimark, David, Booth, Gillian L., Jackevicius, Cynthia A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: CMA Impact Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270657/
https://www.ncbi.nlm.nih.gov/pubmed/37311594
http://dx.doi.org/10.9778/cmajo.20220039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270657/
https://www.ncbi.nlm.nih.gov/pubmed/37311594
http://dx.doi.org/10.9778/cmajo.20220039

Ejemplares similares